Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: the cancer-immunity cycle. Immunity, 39(1), 1–10. https://doi.org/10.1016/j.immuni.2013.07.012.

Article  CAS  PubMed  Google Scholar 

Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer-immune set point. Nature, 541(7637), 321–30. https://doi.org/10.1038/nature21349.

Article  CAS  PubMed  Google Scholar 

Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023). The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity, 56(10), 2188–205. https://doi.org/10.1016/j.immuni.2023.09.011.

Article  CAS  PubMed  Google Scholar 

Zhou, S., Zhu, J., Xu, J., Gu, B., Zhao, Q., Luo, C., Gao, Z., Chin, Y. E., & Cheng, X. (2022). Anti-tumour potential of PD-L1/PD-1 post-translational modifications. Immunology, 167(4), 471–81. https://doi.org/10.1111/imm.13573.

Article  CAS  PubMed  Google Scholar 

Zhao, Y., Harrison, D. L., Song, Y., Ji, J., Huang, J., & Hui, E. (2018). Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells. Cell Reports, 24(2), 379–90.e6. https://doi.org/10.1016/j.celrep.2018.06.054.

Article  CAS  PubMed  Google Scholar 

Zhang, J. Y., Yan, Y. Y., Li, J. J., Adhikari, R., & Fu, L. W. (2020). PD-1/PD-L1 based combinational cancer therapy: Icing on the cake. Frontiers in Pharmacology, 11, 722 https://doi.org/10.3389/fphar.2020.00722.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, T., Li, W., Huang, T., & Zhou, J. (2023). Immunotherapy targeting PD-1/PD-L1 in early-stage triple-negative breast cancer. Journal of Personalized Medicine, 13(3), 526 https://doi.org/10.3390/jpm13030526.

Article  PubMed  PubMed Central  Google Scholar 

Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017). PD-1/PD-L1 blockade: Have we found the key to unleash the antitumor immune response? Frontiers in Immunology, 8, 1597 https://doi.org/10.3389/fimmu.2017.01597.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xing, K., Zhou, P., Li, J., Liu, M., & Zhang, W. E. (2022). Inhibitory effect of PD-1/PD-L1 and blockade immunotherapy in leukemia. Combinatorial Chemistry & High Throughput Screening, 25(9), 1399–410. https://doi.org/10.2174/1574893616666210707101516.

Article  CAS  Google Scholar 

Parvez, A., Choudhary, F., Mudgal, P., Khan, R., Qureshi, K. A., Farooqi, H., & Aspatwar, A. (2023). PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Frontiers in Immunology, 14, 1296341 https://doi.org/10.3389/fimmu.2023.1296341.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pang, K., Shi, Z. D., Wei, L. Y., Dong, Y., Ma, Y. Y., Wang, W., Wang, G. Y., Cao, M. Y., Dong, J. J., Chen, Y. A., Zhang, P., Hao, L., Xu, H., Pan, D., Chen, Z. S., & Han, C. H. (2023). Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade. Drug resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 66, 100907 https://doi.org/10.1016/j.drup.2022.100907.

Article  CAS  PubMed  Google Scholar 

Katsuya, H., Suzumiya, J., & Kimura, S. (2023). Clinical PD-1/PD-L1 blockades in combination therapies for lymphomas. Cancers, 15(22), 5399 https://doi.org/10.3390/cancers15225399.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, W., Zhong, W., Wang, B., Yang, J., Yang, J., Yu, Z., Qin, Z., Shi, A., Xu, W., Zheng, C., Schuchter, L. M., Karakousis, G. C., Mitchell, T. C., Amaravadi, R., Herlyn, M., Dong, H., Gimotty, P. A., Daaboul, G., Xu, X., & Guo, W. (2022). ICAM-1-mediated adhesion is a prerequisite for exosome-induced T-cell suppression. Developmental Cell, 57(3), 329–43.e7. https://doi.org/10.1016/j.devcel.2022.01.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tu, X., Qin, B., Zhang, Y., Zhang, C., Kahila, M., Nowsheen, S., Yin, P., Yuan, J., Pei, H., Li, H., Yu, J., Song, Z., Zhou, Q., Zhao, F., Liu, J., Zhang, C., Dong, H., Mutter, R. W., & Lou, Z. (2019). PD-L1 (B7-H1) competes with the RNA exosome to regulate the DNA damage response and can be targeted to sensitize to radiation or chemotherapy. Molecular Cell, 74(6), 1215–26.e4. https://doi.org/10.1016/j.molcel.2019.04.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pu, Y., & Ji, Q. (2022). Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Frontiers in Immunology, 13, 874589 https://doi.org/10.3389/fimmu.2022.874589.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poggio, M., Hu, T., Pai, C. C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., & Blelloch, R. (2019). Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell, 177(2), 414–27.e13. https://doi.org/10.1016/j.cell.2019.02.016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu, M., Liu, Y., Yi, M., Jiao, D., & Wu, K. (2022). Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer. Frontiers in Immunology, 13, 827921 https://doi.org/10.3389/fimmu.2022.827921.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morrissey, S. M., & Yan, J. (2020). Exosomal PD-L1: Roles in tumor progression and immunotherapy. Trends in cancer, 6(7), 550–8. https://doi.org/10.1016/j.trecan.2020.03.002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu, N., Zhang, J., Yin, M., Liu, H., Zhang, X., Li, J., Yan, B., Guo, Y., Zhou, J., Tao, J., Hu, S., Chen, X., & Peng, C. (2021). Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Molecular Therapy: The Journal of the American Society of Gene Therapy., 29(7), 2321–34. https://doi.org/10.1016/j.ymthe.2021.03.013.

Article  CAS  PubMed  Google Scholar 

Fan, Z., Wu, C., Chen, M., Jiang, Y., Wu, Y., Mao, R., & Fan, Y. (2022). The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation. Acta Pharmaceutica Sinica B, 12(3), 1041–53. https://doi.org/10.1016/j.apsb.2021.09.010.

Article  CAS  PubMed  Google Scholar 

Geng, Q., Jiao, P., Jin, P., Su, G., Dong, J., & Yan, B. (2018). PD-1/PD-L1 inhibitors for immuno-oncology: From antibodies to small molecules. Current Pharmaceutical Design, 23(39), 6033–41. https://doi.org/10.2174/1381612823666171004120152.

Article  CAS  PubMed  Google Scholar 

Cheng, C., Zhuge, L., Xiao, X., Luan, S., & Yuan, Y. (2022). Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer. Frontiers in Oncology, 12, 955163 https://doi.org/10.3389/fonc.2022.955163.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou, Q., Wei, S., Wang, H., Li, Y., Fan, S., Cao, Y., & Wang, C. (2023). T cell-derived exosomes in tumor immune modulation and immunotherapy. Front Immunol, 14, 1130033 https://doi.org/10.3389/fimmu.2023.1130033.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, Y., Liu, T., & Zhou, M. (2022). Immune-cell-derived exosomes for cancer therapy. Molecular Pharmaceutics, 19(9), 3042–56. https://doi.org/10.1021/acs.molpharmaceut.2c00407.

Article  CAS  PubMed  Google Scholar 

Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., & Mi, S. (2015). Exosome and exosomal microRNA: trafficking, sorting, and function. Genomics, Proteomics & Bioinformatics, 13(1), 17–24. https://doi.org/10.1016/j.gpb.2015.02.001.

Article  CAS